{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:35:08Z","timestamp":1778711708332,"version":"3.51.4"},"reference-count":48,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>A safe and effective vaccine that can provide herd immunity against severe acute respiratory syndrome coronavirus (SARS-CoV-2) is urgently needed to stop the spread of this virus among humans. Many human viral vaccines are live, attenuated forms of viruses that elicit humoral and cellular immunity. Here, we describe a cold-adapted live-attenuated vaccine (SARS-CoV-2\/human\/Korea\/CNUHV03-CA22 \u00b0C\/2020) developed by gradually adapting the growth of SARS-CoV-2 from 37 \u00b0C to 22 \u00b0C in Vero cells. This vaccine can be potentially administered to humans as a nasal spray. Its single dose strongly induced neutralising antibodies (titre &gt; 640), cellular immunity, and mucosal IgA antibodies in intranasally immunised K18-hACE2 mice, which are very susceptible to SARS-CoV-2 and SARS-CoV infections. The one-dose vaccinated mice were completely protected from SARS-CoV-2 infection and did not show body weight loss, death, or the presence of virus in tissues, such as the nasal turbinates, brain, lungs, and kidneys. These results demonstrate that the cold-adapted live attenuated SARS-CoV-2 vaccine we have developed may be a candidate SARS-CoV-2 vaccine for humans.<\/jats:p>","DOI":"10.3390\/vaccines8040584","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T07:22:16Z","timestamp":1601709736000},"page":"584","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-8786","authenticated-orcid":false,"given":"Sang Heui","family":"Seo","sequence":"first","affiliation":[{"name":"Laboratory of Influenza Research, College of Veterinary Medicine, Daejeon 34134, Korea"},{"name":"Institute of Influenza Virus, Chungnam National University, Daejeon 34134, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5616-6999","authenticated-orcid":false,"given":"Yunyueng","family":"Jang","sequence":"additional","affiliation":[{"name":"Laboratory of Influenza Research, College of Veterinary Medicine, Daejeon 34134, Korea"},{"name":"Institute of Influenza Virus, Chungnam National University, Daejeon 34134, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China","volume":"382","author":"Zhu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020). The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2, Version 2. Nat. Microbiol., 5, 536\u2013544.","DOI":"10.1038\/s41564-020-0695-z"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.chom.2020.02.001","article-title":"Genome composition and divergence of the novel Coronavirus (2019-nCoV) originating in China","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jmv.25726","article-title":"Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2","volume":"92","author":"Liu","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00831-20","DOI":"10.1128\/JVI.00831-20","article-title":"Comparison of severe acute respiratory syndrome coronavirus 2 spike protein binding to ace2 receptors from human, pets, farm animals, and putative intermediate hosts","volume":"94","author":"Zhai","year":"2020","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"S\u0142yk, S., and Domitrz, I. (2020). Neurological manifestations of SARS-CoV-2\u2014A systemic review. Neurol. Neurochir. Polska.","DOI":"10.5603\/PJNNS.a2020.0050"},{"key":"ref_11","first-page":"e8518","article-title":"Atypical neurological manifestations of COVID-19","volume":"12","author":"Gupta","year":"2020","journal-title":"Cureus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mulligan, M.J., Lyke, K.E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S.P., Neuzil, K., Raabe, V., Bailey, R., and Swanson, K.A. (2020). Phase 1\/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report. MedRxiv.","DOI":"10.1101\/2020.06.30.20142570"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jackson, L.A., Anderson, E.J., Rouphael, N.G., Roberts, P.C., Makhene, M., Coler, R.N., McCullough, M.P., Chappell, J.D., Denison, M.R., and Stevens, L.J. (2020). An mRNA vaccine against SARS-CoV-2\u2014Preliminary report. N. Engl. J. Med., 2022483.","DOI":"10.1056\/NEJMoa2022483"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"H\u00f6rner, C., Sch\u00fcrmann, C., Auste, A., Ebenig, A., Muraleedharan, S., Herrmann, M., Schnierle, B., and M\u00fchlebach, M.D. (2020). A highly immunogenic measles virus-based Th1-biased COVID-19 Vaccine. bioRxiv.","DOI":"10.1101\/2020.07.11.198291"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"30421","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yqhqlom-Ronen, Y., Tamir, H., Melamed, S., Politi, B., Shifman, O., Achdout, H., Vitner, E.B., Israeli, O., Milrot, E., and Stein, D. (2020). A single dose of recombinant VSV-\u0394G-spike vaccine provides protection against SARS-CoV-2 challenge. bioRxiv.","DOI":"10.1101\/2020.06.18.160655"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"ref_20","first-page":"CD004407","article-title":"Vaccines for measles, mumps and rubella in children","volume":"2012","author":"Demicheli","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM196802012780501","article-title":"Live, attenuated mumps-virus vaccine","volume":"278","author":"Hilleman","year":"1968","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0022-3476(66)80490-0","article-title":"Development and characterization of a live attenuated rubella virus","volume":"69","author":"Parkman","year":"2018","journal-title":"J. Pediatrics"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1586\/14760584.6.1.11","article-title":"Rotarix (RIX4414): An oral human rotavirus vaccine","volume":"6","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.287.5.606","article-title":"Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000","volume":"287","author":"Seward","year":"2002","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/biol.1997.0056","article-title":"Yellow fever vaccines","volume":"25","author":"Barrett","year":"1997","journal-title":"Biologicals"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/213612a0","article-title":"Adaptation and growth characteristics of influenza virus at 25 degrees c","volume":"213","author":"Maassab","year":"1967","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1016\/j.vaccine.2008.07.013","article-title":"Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5\u201349 years of age","volume":"26","author":"Block","year":"2008","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Oladunni, F.S., Park, J., Tamayo, P.P., Gonzalez, O., Akhter, A., A-Guardia, A., Olmo-Font\u00e1nez, A., Gautam, S., Garcia-Vilanova, A., and Ye, C. (2020). Lethality of SARS-CoV-2 infection in K18 human angiotensin converting enzyme 2 transgenic mice. bioRxiv.","DOI":"10.1038\/s41467-020-19891-7"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Moreau, G.B., Burgess, S.L., Sturek, J.M., Donlan, A.N., Petri, W.A., and Mann, B.J. (2020). Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection. Am. J. Trop. Med. Hyg., 103.","DOI":"10.1101\/2020.06.26.171033"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rathnasinghe, R., Strohmeier, S., Amanat, F., Gillespie, V.L., Krammer, F., Garc\u00eda-Sastre, A., Coughlan, L., Schotsaert, M., and Uccellini, M. (2020). Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. bioRxiv.","DOI":"10.1101\/2020.07.06.190066"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Winkler, E.S., Bailey, A.L., Kafai, N.M., Nair, S., McCune, B.T., Yu, J., Fox, J.M., Chen, R.E., Earnest, J.T., and Keeler, S.P. (2020). SARS-CoV-2 infection in the lungs of human ACE2 transgenic mice causes severe inflammation, immune cell infiltration, and compromised respiratory function. bioRxiv.","DOI":"10.1101\/2020.07.09.196188"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray","year":"2007","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Euro Surveill."},{"key":"ref_34","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s00705-020-04730-3","article-title":"Gene expression pattern differences in primary human pulmonary epithelial cells infected with MERS-CoV or SARS-CoV-2","volume":"165","author":"Jang","year":"2020","journal-title":"Arch. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13399","DOI":"10.1128\/JVI.79.21.13399-13411.2005","article-title":"The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication","volume":"79","author":"Graham","year":"2005","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12392","DOI":"10.1128\/JVI.01219-08","article-title":"Topology and membrane anchoring of the coronavirus replication complex: Not all hydrophobic domains of nsp3 and nsp6 are membrane spanning","volume":"82","author":"Oostra","year":"2008","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nsmb999","article-title":"Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer","volume":"12","author":"Zhai","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/JVI.78.14.7833-7838.2004","article-title":"Human coronavirus 229E nonstructural protein 13: Characterization of duplex-unwinding, nucleoside triphosphatase, and RNA 5\u2019-triphosphatase activities","volume":"78","author":"Ivanov","year":"2004","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"ref_41","unstructured":"Word Health Organization (2020, July 20). Draft Landscape of COVID-19 Candidate Vaccines. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_42","unstructured":"Centers for Disease Control and Prevention (2020, July 09). Attenuated Influenza Vaccine [LAIV] (The Nasal Spray Flu Vaccine), Available online: https:\/\/www.cdc.gov\/flu\/prevent\/nasalspray.htm."},{"key":"ref_43","unstructured":"Doremalen, N.V., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J.N., Port, J.R., Avanzato, V., Bushmaker, T., Flaxman, A., and Ulaszewska, M. (2020). ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaque. Nature."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ogando, N.S., Dalebout, T.J., Zevenhoven-Dobbe, J.C., Limpens, R.W., Van Der Meer, Y., Caly, L., Druce, J., De Vries, J.J.C., Kikkert, M., and B\u00e1rcena, M. (2020). SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology. J. Gen. Virol., jgv001453.","DOI":"10.1101\/2020.04.20.049924"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2","volume":"368","author":"Shi","year":"2020","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hartman, A.L., Nambulli, S., McMillen, C.M., White, A.G., Tilston-Lunel, N.L., Albe, J.R., Cottle, E., Dunn, M.D., Frye, L.J., and Gilliland, T.H. (2020). SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET\/CT imaging and shedding of infectious virus from both respiratory and gastrointestinal tracts. PLoS Pathog., 16.","DOI":"10.1101\/2020.06.20.137687"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/584\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:16:13Z","timestamp":1760177773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,3]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040584"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040584","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.04.235689","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,3]]}}}